7,498.58

+121.72

+1.65%

52,007.47

+721.74

+1.41%

25,089.01

+509.58

+2.07%

2,786.69

+32.59

+1.18%

4.8470

-0.0120

-0.25%

22.57

-3.07

-11.97%

4,130.50

+55.60

+1.36%

74,884.73

-1,053.27

-1.39%

Crude Oil Dec 26

87.26

-3.57

-3.93%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Nasdaq Real Time Price USD

Eledon Pharmaceuticals, Inc. (ELDN)

2.7300 +0.1250 (+4.80%)

As of 9:49:32 AM EST. Market Open.

Trade ELDN on Coinbase

Loading Chart for ELDN

Chart Range Bar

Interval:

In partnership with ChartIQ

Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting

Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money

Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

Mobilize your Website

View Site in Mobile | Classic

Share by: